In a previous systematic literature search, we demonstrated that the frequencies of antiphospholipid antibodies (aPL) in general-population patients with pregnancy morbidity (PM), deep vein thrombosis (DVT), myocardial infarction (MI), and stroke (ST) are 6%, 10%, 11%, and 14%. To determine the association between aPL and clinical outcomes, we conducted a follow-up analysis of the 120 studies included in the original paper. Based on the analysis of 81 studies, a significant difference in the frequency of aPL criteria tests between patients and controls emerged considering all the outcomes together (10% versus 3%). In particular, a significant difference was reported for overall PM, pregnancy loss (PrL), late PrL, severe preeclampsia (PEC), ST, MI, and DVT. No difference emerged for early PrL, intrauterine growth restriction (IUGR), PEC, eclampsia (EC), and HELLP. A positive association was found in more than half of the studies for overall PrL, severe PEC, HELLP, ST, MI, and DVT and in less than half for early and late PrL, PEC, EC, and IUGR. The positive association between aPL and clinical outcomes included in the antiphospholipid syndrome classification criteria is not supported by every study, being particularly inconsistent for early PL, IUGR, PEC, EC, and HELLP.

The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis : a critical review of the literature / C.B. Chighizola, L. Andreoli, G..R. De Jesus, A. Banzato, G.J. Pons Estel, D. Erkan. - In: LUPUS. - ISSN 0961-2033. - 24:9(2015), pp. 980-984. [10.1177/0961203315572714]

The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis : a critical review of the literature

C.B. Chighizola
;
2015

Abstract

In a previous systematic literature search, we demonstrated that the frequencies of antiphospholipid antibodies (aPL) in general-population patients with pregnancy morbidity (PM), deep vein thrombosis (DVT), myocardial infarction (MI), and stroke (ST) are 6%, 10%, 11%, and 14%. To determine the association between aPL and clinical outcomes, we conducted a follow-up analysis of the 120 studies included in the original paper. Based on the analysis of 81 studies, a significant difference in the frequency of aPL criteria tests between patients and controls emerged considering all the outcomes together (10% versus 3%). In particular, a significant difference was reported for overall PM, pregnancy loss (PrL), late PrL, severe preeclampsia (PEC), ST, MI, and DVT. No difference emerged for early PrL, intrauterine growth restriction (IUGR), PEC, eclampsia (EC), and HELLP. A positive association was found in more than half of the studies for overall PrL, severe PEC, HELLP, ST, MI, and DVT and in less than half for early and late PrL, PEC, EC, and IUGR. The positive association between aPL and clinical outcomes included in the antiphospholipid syndrome classification criteria is not supported by every study, being particularly inconsistent for early PL, IUGR, PEC, EC, and HELLP.
Antiphospholipid antibodies; antiphospholipid syndrome; epidemiology; Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Fetal Growth Retardation; Humans; Lupus Coagulation Inhibitor; Morbidity; Myocardial Infarction; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Stroke; Venous Thrombosis; Rheumatology
Settore MED/16 - Reumatologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
aPL association Lupus 2015.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 81.34 kB
Formato Adobe PDF
81.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/512716
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 40
social impact